Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 227-234

  Rizzo, Jinee ^a,c,f   Levine, Alexandra M ^d   Weiss, Geoff R ^a,b   Pearce, Tillman ^e   Kraynak, Maura ^a,f   Mueck, Robert ^c   Smith, Susan ^a   Von Hoff, Daniel D ^a,b   Kühn, John G ^a,b,c,f  

^a University of Texas Health Science Center at San Antonio   (United States)

^b Division of Oncology ^*  (United States)

^c Department of Pharmacology ^*  (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e St Vincents Midtown Hospital   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

AIDS related non Hodgkin's lymphoma; MGBG; Mitoguazone; Pharmacokinetics

Indexed keywords

ADENOSYLMETHIONINE DECARBOXYLASE; MITOGUAZONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0029840945     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00210796     Document Type: Article

References (14)

1. Warrell RP, Burchenal JH: Methyl-glyoxal-bis (guanylhydrazone) (methyl-GAG): current status and future prospects. J Clin Oncol 1:52-65, 1983
2. Lim SW, Look RM, Bick AB, Hamburg SI, Lawrence ON, Fuerst MP, Kusuanco DA, Kessler CE, Giles FJ: MGBG therapy of relapsed extralymphatic HIV-associated non-Hodgkin's lymphoma (HIV NHL). Proc Am Soc Clin Oncol 14:404, 1995
3. Von Hoff DD: MGBG: Teaching an old drug new tricks. Annals of One 5:487-493, 1994
4. Morris D, Jorstad C, Seyfried CE: Inhibition of the synthesis of polyamines and DNA in activated lymphocytes by a combination of methylornithine and methyl-glyoxal-bis (guanylhydrazone). Cancer Res 37:3169-3172, 1977
5. Burk D, Evans W, Hunter J, Woods M: Primary inhibition of respiration by methylglyoxal-bis (guanylhydra-zone) in L1210 leukemia and other cells, with implica-tions for multiple chemotherapy. Proc Am Assoc Cancer Res 3:308, 1962
6. Marsh K, Repta A, Sternson L: High-performance liquid Chromatographic analysis of the anticancer agent methylglyoxal bis (guanylhydrazone) (MGBG, NSC #32946) in biological fluids. J Chromat 187:101-109, 1980
7. Hart RD, Roboz J, Wu K, Bruckner H, Ohnuma T, Holland JF: Clinical and pharmacological studies with weekly and biweekly methyl-glyoxal bis-guanylhydrazone (methyl-G). Proc Am Assoc Cancer Res 21:181, 1980
8. Marsh KC, Liesmann J, Patton TF, Fabian CJ, Sternson LA: Plasma levels and urinary excretion of methyl-GAG following IV infusion in man. Cancer Treatment Rep 65:253-257, 1981
9. 14C]methylglyoxal-bis(guanylhydrazone) in patients with leukemia. Cancer Res 41:1748-1750, 1981
10. 14. J Pharmacol Exp Ther 141:149-156, 1963
11. Stewart DJ, Rosenblum MG, Luna M, Loo TL: Disposition of methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in man. Cancer Chemother Pharmacol 7: 31-35, 1981
12. Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans. Cancer Res 41:459-462, 1981
13. 14C-WIN 10708-2 in human blood. Sanofi Research Division, Study Report No. 2107, 30 March 1995 (Revised 18 May 1995)
14. Helaszek C: Investigation of human metabolism of WIN 10708-2 using human liver microsomes and precision-cut slices. Sanofi Research Division, Study Report No. 2176, 04 August 1995